Todos Medical Ltd. (OTCQB:TOMDF) said its clinical testing laboratory Provista Diagnostics has entered into two contracts to provide PCR-based monkeypox testing.
The company said under the first agreement, Provista will provide monkeypox-related testing to a New Jersey-based medical group that specializes in the routine screening of patients presenting with dermatologic complaints.
Under the second agreement, the company is expanding a reference laboratory agreement with a New Jersey-based lab that is already sending COVID testing samples to add monkeypox testing.
READ: Todos Medical wins first lab services contract for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
The company noted that while lesion-based testing is the current standard of care for monkeypox per the Centers for Disease Control (CDC) guidelines, both its clinic and laboratory clients have expressed that they are eager to offer the saliva-based sample collection method Provista is currently validating.
According to Todos, saliva-based testing could improve the safety of frontline healthcare workers screening suspected monkeypox cases, with the potential to result in earlier diagnosis and intervention with therapeutic drugs.
Todos CEO Gerald E Commissiong said, since announcing its entrance into the monkeypox testing space, the company has received multiple requests to establish commercial partnerships with physician groups, potential reference lab partners, and municipalities.
“We are moving rapidly to complete the lesion and saliva-based monkeypox tests so that we can begin to service the burgeoning demand and establish Provista as a regional center of excellence for infectious disease and Long COVID testing,” he said.
Todos engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter (NYSE:TWTR) @emilyjjarvie